These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 17504149)

  • 21. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
    Liu GF; Li GJ; Zhao H
    J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
    Lamont EB; Schilsky RL; He Y; Muss H; Cohen HJ; Hurria A; Meilleur A; Kindler HL; Venook A; Lilenbaum R; Niell H; Goldberg RM; Joffe S;
    J Natl Cancer Inst; 2015 Jan; 107(1):336. PubMed ID: 25432408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
    Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ
    Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
    Kamata T; Morita A; Nakamoto A; Onishi I; Takeda T; Koyasaki N; Kanno M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):859-64. PubMed ID: 10897212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
    A'Hern RP; Smith IE; Ebbs SR
    Br J Cancer; 1993 Apr; 67(4):801-5. PubMed ID: 8471439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future treatment options with capecitabine in solid tumours.
    Wilke H
    Eur J Cancer; 2002 Feb; 38 Suppl 2():21-5. PubMed ID: 11841932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
    Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
    Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
    Hatschek T; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Lindh B; Loman N; Malmberg M; Rotstein S; Söderberg M; Sundquist M; Walz TM; Hellström M; Svensson H; Aström G; Brandberg Y; Carstensen J; Fernö M; Bergh J
    Breast Cancer Res Treat; 2012 Feb; 131(3):939-47. PubMed ID: 22094937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
    Luoma ML; Hakamies-Blomqvist L; Sjöström J; Pluzanska A; Ottoson S; Mouridsen H; Bengtsson NO; Bergh J; Malmström P; Valvere V; Tennvall L; Blomqvist C
    Eur J Cancer; 2003 Jul; 39(10):1370-6. PubMed ID: 12826039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
    Lück HJ; Du Bois A; Loibl S; Schrader I; Huober J; Heilmann V; Beckmann M; Stähler A; Jackisch C; Hubalek M; Richter B; Stickeler E; Eidtmann H; Thomssen C; Untch M; Wollschläger K; Schuster T; von Minckwitz G
    Breast Cancer Res Treat; 2013 Jun; 139(3):779-87. PubMed ID: 23771714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant postoperative therapy of gastrointestinal malignancies.
    Ilson DH; Kelsen DP
    Oncology (Williston Park); 1994 Jul; 8(7):75-83; discussion 83, 88-90, 95. PubMed ID: 7917843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.